Meeting
2023 ASCO Annual Meeting
NRG1 fusions in solid tumors.
Authors
Brinda Gupta
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
Brinda Gupta , Sharon Wu , Sai-Hong Ignatius Ou , Sourat Darabi , Kathryn Finch Mileham , Nishant Gandhi , Benjamin Adam Weinberg , Misako Nagasaka , Hossein Borghaei , Patrick C. Ma , Alex Patrick Farrell , George W. Sledge Jr., Ari M. Vanderwalde , Wafik S. El-Deiry , Stephen V. Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3132)
DOI
10.1200/JCO.2023.41.16_suppl.3132
Abstract #
3132
Poster Bd #
330
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Characterization of NRG1 gene fusion events in solid tumors.
First Author: Sushma Jonna
Poster
2019 ASCO Annual Meeting
Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study.
First Author: Alison M. Schram
Poster
2020 ASCO Virtual Scientific Program
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.
First Author: Alison M. Schram
Poster
2019 ASCO Annual Meeting
NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.
First Author: Michaël Duruisseaux